The company says Valeant would cut back on research.

Reports say that Botox-maker Allergan this week will reject the $46 billion take-over offer from rival Valeant Pharmaceuticals, which recently acquired Bausch & Lomb, setting the stage for what the Financial Times calls “a hostile takeover battle at the top of the US drugmaking industry.” Allergan is expected to raise concerns that Valeant would cut research and development as a reason for refusing the offer. The acquisition would create the pre-eminent global powerhouse in the eyecare industry.

Read more at Financial Times | Toronto Star

 
SPONSORED VIDEO: OPTOMETRY WORTH SHARING

HOW TO AVOID AUDIT HELL

You may think you’re ready for a Medicare Audit. But are you? Little things count—but they can mean the difference between a great outcome and one that leaves you out in the cold. Don’t get swallowed up by the audit machine. Get this free guide to preparing for — and surviving — a Medicare Audit. Simply fill out the form to the right to access the information. Because you can survive “Audit Hell” if you’re prepared. Download Audit Kit ➡

Promoted Headlines